Tempus AI Completes Acquisition of Ambry Genetics

Share via:


Tempus AI Completes Acquisition of Ambry Genetics
Tempus AI, an artificial intelligence-driven precision medicine company, has completed its acquisition of Ambry Genetics, a genetic testing company focused on improving health by understanding the relationship between genetics and disease. The deal, valued at USD 600 million, includes USD 375 million in cash and USD 225 million in shares, with USD 100 million subject to a one-year lock-up. Financing was provided by Ares Management Credit Funds.

Also Read: Corti Launches Specialised AI Models for Healthcare

Tempus AI Acquires Ambry Genetics

The…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

admin
admin
Hi! This is Admin.

Popular

More Like this

Tempus AI Completes Acquisition of Ambry Genetics


Tempus AI Completes Acquisition of Ambry Genetics
Tempus AI, an artificial intelligence-driven precision medicine company, has completed its acquisition of Ambry Genetics, a genetic testing company focused on improving health by understanding the relationship between genetics and disease. The deal, valued at USD 600 million, includes USD 375 million in cash and USD 225 million in shares, with USD 100 million subject to a one-year lock-up. Financing was provided by Ares Management Credit Funds.

Also Read: Corti Launches Specialised AI Models for Healthcare

Tempus AI Acquires Ambry Genetics

The…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

admin
admin
Hi! This is Admin.

More like this

PB Fintech Extends Losses, Tumbles Nearly 10% In 2...

SUMMARY PB Fintech shares crashed over 5% in early...

Nvidia GTC 2025: Major announcements on AI, GPUs, quantum...

Nvidia’s GTC 2025 conference is set to reveal...

Capital A to sell BigPay’s majority stake

BigPay is currently the only loss-making entity among...

Popular

Upcoming Events

Fintech Unicorn InCred Finance Raises $30 Mn Debt

SUMMARY InCred Finance’s board passed resolutions to cumulatively issue...

Free Self-Defence Training Sessions By WKMA In Chennai From...

Chennai (Tamil Nadu) , March 12: Ministers from...

iOS 19 redesign will be a big risk for...

Apple is reportedly planning for iOS 19 to...
d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa d.fesdfrwa.dfa